There is a critical need for the development of non-invasive imaging strategies for tuberous sclerosis (TSC) derived tumor lesions in order to monitor the progression and therapeutic efficacy of this multi-system genetic disease. In this study, we investigated the ability of multiparametric 1H MRI (morphological T2-weighted and functional diffusion-weighted) to meet this need in a preclinical murine model of TSC treated with everolimus. Results indicated that proton MR imaging was able to capture the changes in cellularity and tumor size, post treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords